AFP and hepatocellular carcinoma: However, given the limitations of AFP as a stand-alone diagnostic marker, the findings of the present study suggest that CTC-537E7.3 may serve as a complementary biomarker to enhance the accuracy of the diagnosis of HCC and improve patient stratification (Figure 4D).